Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gyros Continues Positive Trend in 2011

Published: Tuesday, May 10, 2011
Last Updated: Tuesday, May 10, 2011
Bookmark and Share
Major biopharmaceutical companies continued to demonstrate their confidence in the Gyros immunoassay platform, with existing accounts investing in additional Gyrolab™ workstations at different sites on both sides of the Atlantic.

The North American market, containing many of the key players involved in global efforts to develop novel biotherapeutics, had a particularly strong start with a revenue growth of 100% compared to the same period in 2010. The number of service providers, such as CRO’s, implementing Gyrolab workstations into their projects also increased.

Commenting on the announcement, Erik Walldén, President and Chief Executive Officer of Gyros AB, said:  “This positive trend confirms that our immunoassay platform is increasingly regarded as an established standard for many time-critical workflows in biotherapeutic development processes. This recognition is also reflected by the interest shown in our annual Gyrolab seminars, held in the USA and Europe, which attract scientists from across the industry.”  Mr. Walldén continued, “Our growing installed base means significant growth in orders for consumables, especially our unique Gyrolab CDs in which the immunoassay steps take place under control of the workstation. Moving forward, Gyros is in an excellent position to set the industry standard for transforming the performance of immunoassays wherever they are utilized within the biopharmaceutical industry.”

The Company’s open, automated platform supports time-critical workflows in the biopharmaceutical industry, boosting productivity and cutting time to result. Automatically running immunoassays at nanoliter scale not only ensures faster development times, but also saves labor, sample and reagents. Assays are readily transferred downstream into GxP environments and between different sites, greatly facilitating collaborations between biopharmaceutical companies and their service providers. Having established the platform in the USA and Europe, Gyros is now focused on building awareness in Asia Pacific, where the Company recently announced that it has appointed a network of distributors.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gyros Announces Changes to its Management Team
Dr. Jon-Sverre Schanche becomes Chief Technology Officer and Vice President Technical Affairs.
Monday, October 24, 2011
Gyros Wins SwedenBIO Award 2011
Company selected to receive the award based on the international success of the Gyros immunoassay platform.
Friday, May 27, 2011
Gyros platform enters leading US Clinical Research Organization
CEDRA Corporation, a division of Worldwide Clinical Trials, invests in Gyrolab workstation
Tuesday, March 16, 2010
Gyros Platform Ramps Up Immunoassay Capacity at ICON Development Solutions
CRO purchases third Gyrolab workstation to develop and run immunoassays.
Friday, March 12, 2010
Gyros and SCRUM Sign Distribution Agreement for the Japanese Market
SCRUM will market, sell and fully support the Gyros product range, within the Japanese life-science market industries.
Wednesday, February 17, 2010
Gyros has Completed the Separate Sales of two Microfluidic System Platforms
Gyros platform for protein quantification is purchased by AstraZeneca and Cambridge Antibody Technology.
Wednesday, August 09, 2006
Gyros Awarded Frost & Sullivan Technology of the Year Award
The award recognizes the company’s technology development and overall technical excellence.
Wednesday, November 16, 2005
Gyros AB licenses technology to Cellectricon AB

Tuesday, April 15, 2003
Gyros expands with German office

Monday, December 02, 2002
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Experimental Therapy For Brain Cancer Could Prevent Drug Resistance
Information from penny-sized microfluidic chips allowed researchers to anticipate resistance to cancer treatment.
3D Printing of Lego Fluidics
Study shows how 3D printing can open up microfluidic technology to a wider audience.
New Method to Preserve Device to Monitor HIV Treatment
Inspired by pregnancy tests, scientists have developed a method to store microfluidic devices for months without refrigeration, giving developing countries an inexpensive and reliable way to treat patients.
Migration Creates Cancer Cell Vulnerabilities
Scientists found that migration can damage cancer cells’ nuclei and DNA, requiring repairs for their survival. The results may open new avenues for targeting metastatic cancer.
Liver-On-Chip Tracks Dynamics of Cellular Function
Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!